 If a patient meets the baseline enrollment criteria, approximately 5-10 grams of skeletal muscle is obtained from the subjects leg muscle for myoblast isolation and expansion in vitro MyoCellTM at a specified off site cGMP culture laboratory. The expanded myoblast cells, MyoCellTM will be implanted into the akinetic myocardial scar in the region of a previous infarct utilizing Biohearts MyoCathTM transendocardial delivery catheter system. The MyoCathTM endoventricular device is expected to deliver the MyoCellTM autologous skeletal myoblast cells into the scarred myocardial region by steering a catheter which contains a retractable hypodermic needle to the targeted sites for implantation. 